Fused ring compounds as KRas G12D inhibitors

By developing fused-ring compounds that inhibit KRas G12D protein, the problem of insufficient efficacy of existing KRas G12D inhibitors has been solved, and effective treatment of KRas G12D mutant tumors has been achieved.

CN117751116BActive Publication Date: 2026-11-17WIGEN BIOMEDICINE TECH (SHANGHAI) CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202280047839.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2021-07-07
Filing Date
2022-07-07
Publication Date
2026-11-17
Estimated Expiration
2042-07-07

AI Technical Summary

Technical Problem

Existing technologies are unable to effectively inhibit KRas G12D protein, resulting in a lack of outstanding efficacy and safety in the treatment of related tumors.

Method used

A class of fused-ring compounds with KRas G12D protein inhibitory activity has been developed for the preparation of drugs to treat, regulate or prevent KRas G12D-mediated diseases by synthesizing compounds of general formula (1) and their isomers, pharmaceutically acceptable salts, hydrates or solvates.

Benefits of technology

The compound exhibits potent KRas G12D inhibitory activity and has potential clinical application value in treating KRas G12D mutation-related tumors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117751116B_ABST
    Figure CN117751116B_ABST
Patent Text Reader

Abstract

A class of fused-ring compounds that act as KRas G12D inhibitors. Specifically, this relates to a compound of general formula (1) and its preparation method, and the use of the compound of general formula (1) and its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates as KRas G12D inhibitors. This compound and its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates can be used to prepare drugs for the treatment or prevention of KRas G12D-mediated diseases.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application claims priority to Chinese patent application 2021107672086, filed on July 7, 2021. The entire contents of the aforementioned Chinese patent application are incorporated herein by reference. Technical Field

[0002] This invention relates to the field of medicinal chemistry, and more specifically, to a class of fused-ring compounds with KRas G12D protein inhibitory activity, their preparation methods, and the application of such compounds in the preparation of drugs for treating, regulating, or preventing KRas G12D-mediated diseases. Background Technology

[0003] KRas (Kirsten Rat Sarcoma 2 Viral Oncogene Homolog) is a class of GTPases and a member of the Ras family of oncogenes. In cells, KRas proteins exist in both GDP-binding (inactive) and GTP-binding (activated) forms. These two forms interconvert to transmit activation signals from various upstream tyrosine kinases to downstream effector proteins, thereby regulating a range of important physiological functions, such as cell proliferation.

[0004] Research over the past three decades has shown that activated KRas proteins play a crucial role in tumorigenesis. Aberrant expression of KRas proteins is associated with approximately 20% of all cancer cases. Oncogenic KRas mutations stabilize the binding of GTP to mutant KRas proteins, leading to persistent activation of KRas proteins and downstream signaling pathways. Studies have reported that up to 25-30% of lung adenocarcinoma cases contain this type of KRas mutation. The KRas G12D mutation is the most common KRas mutation. Studies have shown that the KRas G12D mutation is present in 25% of patients with pancreatic ductal carcinoma, 13.3% of patients with colon adenocarcinoma, 10.1% of patients with rectal adenocarcinoma, 4.1% of patients with non-small cell lung cancer, and 1.7% of patients with small cell lung cancer.

[0005] The important role of KRas in cancer development and the discovery that KRas mutations are common in many tumors make KRas a very attractive target. Although a large number of studies have been conducted over the past 30 years to search for KRas inhibitors, apart from the KRasG12C irreversible inhibitors that have been observed to have efficacy in clinical trials, no other KRas inhibitors have shown outstanding efficacy and safety in clinical trials to date.

[0006] Therefore, the development of specific, highly active small molecule inhibitors of KRas G12D has important clinical value for the treatment of tumors with KRas G12D mutations. Summary of the Invention

[0007] This invention provides a compound of general formula (1) or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates:

[0008]

[0009] In general formula (1):

[0010] R 1 -H, -OH, halogen, (C1-C3)alkyl, nitrile-substituted (C1-C3)alkyl, hydroxyl-substituted (C1-C3)alkyl, HC(=O)-, -CO2R 5 -CO2N(R) 5 )2 or (5-6 yuan) heteroaryl;

[0011] Y is O or NR 5 ;

[0012] Ring A is phenyl, (5-7 membered) heteroaryl, (C5-C7) cycloalkyl, or (5-7 membered) heterocycloalkyl;

[0013] Each R 2 Independently, it is -H, halogen, (C1-C3)alkyl, (C1-C3)haloalkyl, (C1-C3)haloalkoxy, (C6-C14)aryl, or (5-14-membered)heteroaryl, wherein the (C1-C3)alkyl, (C1-C3)haloalkyl, (C1-C3)haloalkoxy, (C6-C14)aryl, or (5-14-membered)heteroaryl may each be independently optionally surrounded by 1, 2, 3, or 4 Rs. 6 replace;

[0014] Each R 3 Independently -H, halogen, -OH, (C1-C3)alkyl, hydroxyl-substituted (C1-C3)alkyl, (C1-C3)haloalkyl, (C1-C3)alkoxy, (5-7 member) heteroaryl, -CN, -SO2F, NHC(O)R 8 -N(R) 5 2. -CH2OC(O)N(R 5 )2、-CH2NHC(O)OR 7 -CH2NHC(O)N(R) 5 )2、-CH2NHC(O)R 7 -CH2NHS(O)2R 7 -CH2OC(O)R 8 -OC(O)N(R) 5 2、-OC(O)NH(CH2)m OR 7 -OC(O)NH(CH2) m O(CH2) n R 8 -OC(O)R 8 -CH2R 8 The (C1-C3)alkyl, hydroxy-substituted (C1-C3)alkyl, (C1-C3)haloalkyl, (C1-C3)alkoxy, or (5-7)heteroaryl groups may each be independently and optionally substituted with 1, 2, 3, or 4 of the following groups: -H, halogen, R 7 and R 8 Or when two R 3 When connected to the same atom, two R 3 It can form an oxygen group;

[0015] Q represents a chemical bond or O;

[0016] Ring B is (C5-C7) cycloalkyl, phenyl, (5-7-membered) heteroaryl, or (5-7-membered) heterocycloalkyl;

[0017] Each R 4 Independently -H, -D, halogen, R 9 -OH, -(CH2) n OR 9 -(CH2) n NR 9 R 10 -OR 9 -NR 9 R 10 -CN, -C(O)NR 9 R 10 -NR 10 C(O)R 9 -NR 10 S(O)2R 9 -S(O) p R 9 -S(O)2NR 9 R 10 (C1-C6)alkyl, (C1-C6)haloalkyl, (C2-C6)alkenyl, (C2-C6)ynyl, or (C3-C9)cycloalkyl, wherein the (C1-C6)alkyl, (C1-C6)haloalkyl, (C2-C6)alkenyl, (C2-C6)ynyl, or (C3-C9)cycloalkyl may each be independently optionally substituted with 1, 2, 3, or 4 of the following groups: -H, halogen, R 7 -OH, -(CH2) n OR 7 -(CH2) n N(R7 )2、-OR 7 -N(R) 7 )2、-CN、-C(O)N(R 7 )2、-NR 7 C(O)R 7 -NR 7 S(O)2R 7 -S(O) p R 7 and -S(O)2N(R 7 )2; or when two R 4 When connected to the same atom, two R 4 It can form an oxygen group;

[0018] Each R 5 Independently -H or (C1-C3) alkyl;

[0019] R 6 -H, halogen, -OH, -CN, -OR 7 -SR 7 (C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)alkynyl, (5-7 member)heteroaryl, (C1-C4)haloalkyl, (C1-C4)alkoxy, -CH2C(=O)N(R 5 )2、-N(R 5 2 or (C3-C6)cycloalkyl, wherein the (C1-C4)alkyl, (C2-C4)alkenyl, (C2-C4)ynyl, (5-7)heteroaryl, (C1-C4)haloalkyl, (C1-C4)alkoxy, or (C3-C6)cycloalkyl may each be independently and optionally substituted with 1, 2, 3, or 4 of the following groups: -H, -D, halogen, -OH, -NH2, -CN, and R 7 ;

[0020] Each R 7 It is independently (C1-C6)alkyl, (C1-C6)haloalkyl, or (C1-C3)alkoxy;

[0021] Each R 8 It is independently a (5-7-membered) heterocyclic alkyl, (5-7-membered) heteroaryl or phenyl group, wherein the (5-7-membered) heterocyclic alkyl, (5-7-membered) heteroaryl or phenyl group may each be independently optionally substituted with 1, 2, 3 or 4 of the following groups: -H, -OH, -CN, -C(O)H, -(CH2). n OR 7 and -(CH2) n N(R 7 )2;

[0022] R 9and R 10 Each is independently -H, (C1-C6)alkyl or (C3-C7)cycloalkyl, or R on the same nitrogen atom. 9 and R 10 The N atoms bonded to them can collectively form a (3-7 membered) heterocyclic alkyl group, which may optionally be substituted with 1, 2, 3, or 4 of the following groups: -H, halogen, (C1-C3)alkyl, (C3-C5)cycloalkyl, or (C1-C3)alkoxy; and

[0023] p is an integer of 0, 1, or 2; r is an integer of 1, 2, 3, or 4; s is an integer of 0, 1, 2, 3, or 4; t is an integer of 0, 1, 2, 3, or 4; n is an integer of 0, 1, 2, or 3; and m is an integer of 1, 2, or 3.

[0024] In another preferred embodiment, in the general formula (1), R 1 -H, -OH, -F HC(=O)-, -CO2CH3 or -CO2N(CH3)2.

[0025] In another preferred embodiment, Y in the general formula (1) is O, NH or NCH3.

[0026] In another preferred embodiment, wherein in the general formula (1), ring A is phenyl, 6-membered heteroaryl, cyclohexyl or (5-6-membered) heterocyclic alkyl.

[0027] In another preferred embodiment, in the general formula (1), ring A is: The * symbol is attached to one end of a nitrogen atom.

[0028] In another preferred embodiment, wherein in the general formula (1), each R 2 Independently, it is -H, -F, -Cl, -Br, -I, (C1-C3)alkyl, (C1-C3)haloalkyl, (C1-C3)haloalkoxy, (C6-C14)aryl, or (5-14-membered)heteroaryl, wherein the (C1-C3)alkyl, (C1-C3)haloalkyl, (C1-C3)haloalkoxy, (C6-C14)aryl, or (5-14-membered)heteroaryl may each be independently and optionally substituted with 1, 2, 3, or 4 of the following groups: -H, -F, -Cl, -Br, -I, -OH, -CN, -OCH3, -OCH2CH3, -OCH(CH3)2, -OCF3, -OCHF2, -OCH2CF3, -SCH3, -SCH2CH3, -N(CH3)2, -NH2, -NH(CH3). -SCF3,

[0029] In another preferred embodiment, in the general formula (1), the structural unit for:

[0030]

[0031]

[0032]

[0033]

[0034]

[0035]

[0036]

[0037]

[0038]

[0039] In another preferred embodiment, wherein in the general formula (1), each R 3 Independently -H, -OH, -F, -Cl, -Br, -I, (C1-C3)alkyl, hydroxyl-substituted (C1-C3)alkyl, (C1-C3)haloalkyl, (C1-C3)alkoxy, (5-6 member) heteroaryl, -CN, NHC(O)R 8 -N(R) 5 )2、-CH2OC(O)N(R 5 )2、-CH2NHC(O)OR 7 -CH2NHC(O)N(R) 5 )2、-CH2NHC(O)R 7 -CH2NHS(O)2R 7 -CH2OC(O)R 8 -OC(O)N(R) 5 2、-OC(O)NH(CH2) m OR 7 -OC(O)NH(CH2) m O(CH2) n R 8 -OC(O)R 8 -CH2R 8The (C1-C3) alkyl, hydroxy-substituted (C1-C3) alkyl, (C1-C3) haloalkyl, (C1-C3) alkoxy, or (5-6) heteroaryl groups may each be independently and optionally substituted by 1, 2, 3, or 4 of the following groups: -H, -F, -CH3, -OCH3, or -CH2CH3; or when two R 3 When connected to the same atom, two R 3 It can form an oxygen group.

[0040] In another preferred embodiment, wherein in the general formula (1), each R 3 Independently: -H, -OH, -F, -Cl, -Br, -I, -CN, -SO2F, -OCH3, -CF3

[0041] In another preferred embodiment, wherein in the general formula (1), ring B is (C5-C6)cycloalkyl, phenyl, (5-6) heteroaryl, or (5-6) heterocycloalkyl.

[0042] In another preferred embodiment, in the general formula (1), ring B is:

[0043]

[0044] The * symbol is attached to one end of a nitrogen atom.

[0045] In another preferred embodiment, wherein in the general formula (1), each R 4 Independently -H, -D, -F, -Cl, -Br, -I, -OH, -CH2OR 9 -CH2NR 9 R 10 -OR 9 -NR 9 R 10 -CN, -C(O)NR 9 R 10 -NR 10 C(O)R 9 -NR 10 S(O)2R 9 -SR 9 -S(O)2R 9 -S(O)2NR 9 R 10(C1-C3)alkyl, (C1-C3)haloalkyl, (C2-C4)alkenyl, (C2-C4)ynyl, or (C3-C6)cycloalkyl, wherein the (C1-C3)alkyl, (C1-C3)haloalkyl, (C2-C4)alkenyl, (C2-C4)ynyl, or (C3-C6)cycloalkyl may each be independently and optionally substituted with 1, 2, 3, or 4 of the following groups: -H, -F, -Cl, -Br, -I, -OH, -OCH3, -N(CH3)2, and -CN; or when two R 4 When connected to the same atom, two R 4 It can form an oxygen group.

[0046] In another preferred embodiment, wherein in the general formula (1), each R 4 Independently: -H, -D, -F, -Cl, -Br, -I, -OH, -CH2OCH3, -CH2N(CH3)2, -OCH3, -OCF3, -N(CH3)2, -CN, -C(O)NH2, -C(O)NH(CH3), -C(O)N(CH3)2, -NHC(O)CH3, -N(CH3)-C(O)CH3, -NHS(O)2CH3, -NCH3S(O)2CH3, -SCH3, -S(O)2CH3 and -S(O)2NH2, -S(O)2NH(CH3), -S(O)2N(CH3)2 Or when two R 4 When connected to the same atom, two R 4 It can form an oxygen group.

[0047] In another preferred embodiment, in the general formula (1), the structural unit for:

[0048]

[0049]

[0050]

[0051] In another preferred embodiment, the general formula (1) has a structure as shown in general formula (1a) or general formula (1b):

[0052]

[0053] Where R 1 R 2 R 3 R 4 The definitions of Y, B, r, s, and t are as described above, and exemplified in the embodiments.

[0054] In another preferred embodiment, the general formula (1) has the structure shown in general formulas (2a) to (2d):

[0055]

[0056] Where R 1 R 2 R 3 R 4 The definitions of Y, r, s, and t are as described above, and illustrated in the embodiments.

[0057] In various embodiments, the compound of general formula (1) has one of the following structures:

[0058]

[0059]

[0060]

[0061]

[0062]

[0063]

[0064]

[0065]

[0066]

[0067]

[0068]

[0069]

[0070]

[0071]

[0072] Another object of the present invention is to provide a pharmaceutical composition comprising a pharmaceutically acceptable carrier, a diluent and / or an excipient, and a compound of general formula (1) of the present invention, or its isomers, crystal forms, pharmaceutically acceptable salts, hydrates or solvates as active ingredients.

[0073] Another object of the present invention is to provide the use of the compound of general formula (1) of the present invention, or any isomer thereof, crystal form thereof, pharmaceutically acceptable salt, hydrate or solvate thereof, or the pharmaceutical composition thereof, in the preparation of a medicament for treating, regulating or preventing diseases associated with KRas G12D; wherein the disease is preferably cancer, and the cancer is hematologic malignancy and solid tumor.

[0074] Another object of the present invention is to provide a method for treating, modulating or preventing diseases associated with KRas G12D, comprising administering to a subject a therapeutically effective amount of a compound of general formula (1) of the present invention, or any isomer, crystal form, pharmaceutically acceptable salt, hydrate or solvate thereof, or a pharmaceutical composition thereof; wherein the disease is preferably cancer, the cancer being hematologic malignancy or solid tumor.

[0075] Through the synthesis and careful study of a number of new compounds involving KRas G12D protein inhibition, the inventors discovered that the compound of general formula (1) unexpectedly possesses strong KRas G12D inhibitory activity.

[0076] It should be understood that the foregoing general description of the invention and the following detailed description are exemplary and illustrative, and are intended to provide further explanation of the claimed invention.

[0077] Compound Synthesis

[0078] The preparation method of the compound of general formula (1) of the present invention is described in detail below, but these specific methods do not constitute any limitation on the present invention.

[0079] The compounds of general formula (1) described above can be synthesized using standard synthetic techniques or known techniques combined with the methods described herein. Furthermore, the solvents, temperatures, and other reaction conditions mentioned herein can be varied. Starting materials used for the synthesis of the compounds can be obtained synthetically or from commercial sources. The compounds described herein and other related compounds with different substituents can be synthesized using known techniques and starting materials, including those discovered in March, ADVANCED ORGANIC CHEMISTRY 4. th Ed., (Wiley 1992); Carey and Sundberg, ADVANCED ORGANIC CHEMISTRY 4 th Ed., Vols.A and B (Plenum 2000, 2001), Green and Wuts, PROTECTIVE GROUPS IN ORGANIC SYNTHESIS 3 rdThe method described in Ed. (Wiley 1999) can be used to prepare compounds by employing appropriate reagents and by introducing different groups into the molecular formulas provided herein.

[0080] On the one hand, the compounds described herein are prepared according to methods known in the art. However, the conditions of the method, such as reactants, solvents, bases, amounts of compounds used, reaction temperatures, and reaction times, are not limited to the explanations below. The compounds of the present invention can also be conveniently prepared by combining various synthetic methods described in this specification or known in the art, such combinations being readily performed by those skilled in the art. On the other hand, the present invention also provides a method for preparing the compound of general formula (1), wherein the compound of general formula (1) can be prepared using the following general reaction procedure 1 or general reaction procedure 2:

[0081] General reaction process 1

[0082]

[0083] Compounds of general formula (1) can be prepared according to general reaction procedure 1, wherein R 1 R 2 R 3 R 4 As defined above, rings Y and B represent hydrogen, N represents nitrogen, S represents sulfur, O represents oxygen, and X represents nitrogen or carbon. As shown in the general reaction flow 1, compounds 1-1 and 1-2 undergo a substitution reaction under basic conditions to generate compound 1-3. Compound 1-3 reacts with either 1-4 or 1-5 to generate compound 1-6. Compound 1-6 reacts under acidic conditions to generate compound 1-7. Compound 1-7 reacts with compound 1-8 to generate compound 1-9. Compound 1-9 reacts with POCl3 to generate compound 1-10. Compound 1-10 and compound 1-11 undergo a substitution reaction to generate compound 1-12. Compound 1-12 and 1-13 undergo a substitution reaction to generate compound 1-14. Compound 1-14 undergoes a deprotection reaction under acidic conditions to generate compound 1-15.

[0084] General reaction process 2

[0085]

[0086] Compounds of general formula (1) can be prepared according to general reaction procedure 2, wherein R 1 R 2 R 3 R 4The Y and B rings are as defined above, H represents hydrogen, N represents nitrogen, S represents sulfur, and O represents oxygen. As shown in the general reaction flow 2, compounds 2-1 and 2-2 undergo a substitution reaction under basic conditions to generate compound 2-3. Compound 2-3 and 2-4 undergo a substitution reaction to generate compound 2-5. Compound 2-5 undergoes selective deprotection under acidic conditions to generate 2-6. Compound 2-6 undergoes a coupling reaction with compounds 2-7 or 2-8 to generate compound 2-9. Compound 2-9 undergoes deprotection under acidic conditions to generate 2-10.

[0087] Further forms of the compound

[0088] "Pharmaceutical acceptable" here means that a substance, such as a carrier or diluent, will not destroy the biological activity or properties of a compound and is relatively non-toxic. For example, when given to an individual, a substance will not cause unwanted biological effects or interact with any of its components in a harmful manner.

[0089] The term "pharmaceutically acceptable salt" refers to a form of a compound that does not cause significant irritation to the administered organism and does not diminish the compound's biological activity and properties. In some specific respects, pharmaceutically acceptable salts are obtained by reacting compounds of general formula (1) with acids, such as inorganic acids like hydrochloric acid, hydrobromic acid, hydrofluoric acid, sulfuric acid, phosphoric acid, nitric acid, and carbonic acid; organic acids like formic acid, acetic acid, propionic acid, oxalic acid, trifluoroacetic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, picric acid, methanesulfonic acid, benzenesulfonic acid, and p-toluenesulfonic acid; and acidic amino acids like aspartic acid and glutamic acid.

[0090] It should be understood that references to pharmaceutically acceptable salts include solvent-added forms or crystalline forms, especially solvates or polymorphs. Solvates contain stoichiometric or non-stoichiometric solvents and are selectively formed during crystallization with pharmaceutically acceptable solvents such as water, ethanol, etc. A hydrate is formed when the solvent is water, or an alcohol is formed when the solvent is ethanol. Solvates of compounds of general formula (1) are readily prepared or formed according to the methods described herein. For example, hydrates of compounds of general formula (1) are readily prepared by recrystallization from a mixture of water and organic solvents, including but not limited to tetrahydrofuran, acetone, ethanol, or methanol. Furthermore, the compounds mentioned herein can exist in both solvated and non-solvated forms. In summary, for the purposes of the compounds and methods provided herein, the solvated form is considered equivalent to the non-solvated form.

[0091] In other specific embodiments, compounds of general formula (1) are prepared in various forms, including but not limited to amorphous, pulverized, and nano-particle forms. Furthermore, compounds of general formula (1) include crystalline forms and can also be polymorphic. Polymorphs comprise different lattice arrangements of the same elemental composition of the compound. Polymorphs typically have different X-ray diffraction spectra, infrared spectra, melting points, densities, hardness, crystal forms, optical and electrical properties, stability, and solubility. Different factors such as recrystallization solvents, crystallization rates, and storage temperatures may cause a single crystal form to dominate.

[0092] In another aspect, compounds of general formula (1) may possess a chiral center and / or axial chirality, and thus appear as racemates, racemic mixtures, single enantiomers, diastereomers, and single diastereomers, and cis-trans isomers. Each chiral center or axial chirality will independently produce two optical isomers, and all possible optical isomers and diastereomer mixtures, as well as pure or partially pure compounds, are included within the scope of this invention. This invention means including all such isomeric forms of these compounds.

[0093] The compounds of this invention may contain atomic isotopes in non-natural proportions on one or more atoms constituting the compound. For example, the compounds may be labeled with radioactive isotopes, such as tritium. 3 H), Iodine-125 ( 125 I) and C-14 14 C). For example, deuterium can be used to replace hydrogen atoms to form deuterated compounds. The bond between deuterium and carbon is stronger than that between ordinary hydrogen and carbon. Compared with undeuterated drugs, deuterated drugs generally have advantages such as reduced toxicity, increased drug stability, enhanced efficacy, and prolonged drug half-life in vivo. All isotopic variations of the compounds of this invention, regardless of radioactivity, are included within the scope of this invention.

[0094] the term

[0095] Unless otherwise specified, the terms used in this application, including the specification and claims, are defined as follows. It must be noted that in the specification and appended claims, unless otherwise clearly indicated, the singular form "a" includes the plural meaning. Unless otherwise specified, conventional methods such as mass spectrometry, nuclear magnetic resonance, HPLC, protein chemistry, biochemistry, recombinant DNA techniques, and pharmacology are used. In this application, unless otherwise specified, "or" or "and" refers to "and / or".

[0096] Unless otherwise specified, "alkyl" refers to a saturated aliphatic hydrocarbon group, including straight-chain and branched groups with 1 to 6 carbon atoms. Lower alkyl groups containing 1 to 4 carbon atoms are preferred, such as methyl, ethyl, propyl, 2-propyl, n-butyl, isobutyl, and tert-butyl. As used herein, "alkyl" includes unsubstituted and substituted alkyl groups, especially alkyl groups substituted with one or more halogens. Preferred alkyl groups are selected from CH3, CH3CH2, CF3, CHF2, CF3CH2, CF3(CH3)CH, etc. i Pr、 n Pr、 i Bu、 n Bu or t Bu.

[0097] Unless otherwise specified, "alkylene" means a divalent alkyl group as defined above. Examples of alkylene groups include, but are not limited to, methylene and ethylene.

[0098] Unless otherwise specified, "alkenyl" refers to an unsaturated aliphatic hydrocarbon group containing a carbon-carbon double bond, including straight-chain or branched groups with 1 to 14 carbon atoms. Lower alkenyl groups containing 1 to 4 carbon atoms are preferred, such as vinyl, 1-propenyl, 1-butenyl, or 2-methylpropenyl.

[0099] Unless otherwise specified, "alkynyl" refers to an unsaturated aliphatic hydrocarbon group containing a carbon-carbon triple bond, including straight-chain and branched groups with 1 to 14 carbon atoms. Lower alkynyl groups containing 1 to 4 carbon atoms are preferred, such as ethynyl, 1-propynyl or 1-butynyl.

[0100] Unless otherwise specified, "cycloalkyl" refers to a non-aromatic hydrocarbon ring system (monocyclic, bicyclic, or polycyclic). A partially unsaturated cycloalkyl group may be referred to as "cycloalkenyl" if the carbon ring contains at least one double bond, or as "cycloynyl" if the carbon ring contains at least one triple bond. Cycloalkyl groups may include monocyclic or polycyclic (e.g., having 2, 3, or 4 fused rings) groups and spirocyclic groups. In some embodiments, the cycloalkyl group is monocyclic. In some embodiments, the cycloalkyl group is monocyclic or bicyclic. The cycloforming carbon atom of the cycloalkyl group may optionally be oxidized to form an oxo or thio group. Cycloalkyl groups also include cycloalkylene groups. In some embodiments, the cycloalkyl group contains 0, 1, or 2 double bonds. In some embodiments, the cycloalkyl group contains 1 or 2 double bonds (partially unsaturated cycloalkyl). In some embodiments, the cycloalkyl group may be fused with aryl, heteroaryl, cycloalkyl, and heterocyclic alkyl groups. In some embodiments, the cycloalkyl group may be fused with aryl, cycloalkyl, and heterocyclic alkyl groups. In some embodiments, the cycloalkyl group may be fused with aryl and heterocyclic alkyl groups. Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, cyclopentenyl, cyclohexenyl, cyclohexadienyl, cyclohepttrienyl, norcamphenyl, norpinel, norcarel, bicyclo[1.1.1]pentyl, bicyclo[2.1.1]hexyl, and so on.

[0101] Unless otherwise specified, "alkoxy" refers to an alkyl group bonded to the remainder of the molecule via an ether oxygen atom. Representative alkoxy groups are those having 1-6 carbon atoms, such as methoxy, ethoxy, propoxy, isopropoxy, butoxy, isobutoxy, sec-butoxy, and tert-butoxy. As used herein, "alkoxy" includes unsubstituted and substituted alkoxy groups, particularly those substituted with one or more halogens. Preferred alkoxy groups are selected from OCH3, OCF3, CHF2O, CF3CH2O, etc. i- PrO, n- PrO, i- BuO、 n- BuO or t- BuO.

[0102] Unless otherwise specified, "aryl" refers to a hydrocarbon aromatic group, which can be monocyclic or polycyclic, such as a monocyclic aryl ring fused with one or more carbocyclic aromatic groups. Examples of aryl groups include, but are not limited to, phenyl, naphthyl, and phenanthrene.

[0103] Unless otherwise specified, "aryloxy group" refers to an aryl group bonded to the rest of the molecule via an ether oxygen atom. Examples of aryloxy groups include, but are not limited to, phenoxy and naphthoxy groups.

[0104] Unless otherwise specified, "arylene" refers to a divalent aryl group as defined above. Examples of arylene groups include, but are not limited to, phenylene, naphthylene, and phenanthrene.

[0105] Unless otherwise specified, "heteroaryl" refers to an aromatic group containing one or more heteroatoms (O, S, or N), which may be monocyclic or polycyclic. For example, a monocyclic heteroaryl ring may be fused with one or more carbocyclic aromatic groups or other monocyclic heterocyclic alkyl groups. Examples of heteroaryl groups include, but are not limited to, pyridinyl, pyridazinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, quinolinyl, isoquinolinyl, furanyl, thiopheneyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrroleyl, indolyl, benzimidazolyl, benzofuranyl, benzothiazolyl, benzothiaphenyl, benzoxazolyl, benzopyridinyl, pyrrolopyrimidinyl, 1H-pyrrole[3,2-b]pyridinyl, 1H-pyrrole[2,3-c]pyridinyl, 1H-pyrrole[3,2-c]pyridinyl, 1H-pyrrole[2,3-b]pyridinyl,

[0106] Unless otherwise specified, “hybrid aryl” refers to a divalent heteroaryl group as defined above.

[0107] Unless otherwise specified, "heterocyclic alkyl" refers to a non-aromatic ring or ring system that may optionally contain one or more alkenyl groups as part of a ring structure, having at least one heteroatom ring member independently selected from boron, phosphorus, nitrogen, sulfur, oxygen, and phosphorus. If a heterocyclic alkyl contains at least one double bond, then a partially unsaturated heterocyclic alkyl may be referred to as a "heterocyclic alkenyl," or if a heterocyclic alkyl contains at least one triple bond, then a partially unsaturated heterocyclic alkyl may be referred to as a "heterocyclic ynyl." Heterocyclic alkyl can include monocyclic, bicyclic, spirocyclic, or polycyclic (e.g., having two fused or bridging rings) ring systems. In some embodiments, a heterocyclic alkyl is a monocyclic group having one, two, or three heteroatoms independently selected from nitrogen, sulfur, and oxygen. The cyclic carbon atom and heteroatom of a heterocyclic alkyl may optionally be oxidized to form an oxo or thio ion group or other oxidized bond (e.g., C(O), S(O), C(S), or S(O)₂, N-oxide, etc.), or the nitrogen atom may be quaternized. Heterocyclic alkyl may be linked via cyclic carbon atoms or cyclic heteroatoms. In some embodiments, the heterocyclic alkyl group contains 0 to 3 double bonds. In some embodiments, the heterocyclic alkyl group contains 0 to 2 double bonds. The definition of heterocyclic alkyl group also includes a portion having one or more aromatic rings fused with (i.e., sharing bonds with) the heterocyclic alkyl ring, such as benzo[a] derivatives of piperidine, morpholine, aziridine-heptadiene, or thiophene. Heterocyclic alkyl groups containing fused aromatic rings can be linked via any cyclizing atom, including the cyclizing atom of the fused aromatic ring. Examples of heterocyclic alkyl groups include, but are not limited to, azirrobutyl, azirroheptyl, dihydrobenzofuranyl, dihydrofuranyl, dihydropyranyl, N-morpholinyl, 3-oxa-9-azaspiro[5.5]undecyl, 1-oxa-8-azaspiro[4.5]decyl, piperidinyl, piperazinyl, oxoperazinyl, pyranyl, pyrrolidinyl, quininyl, tetrahydrofuranyl, tetrahydropyranyl, 1,2,3,4-tetrahydroquinolinyl, scopolamine, 4,5,6,7-tetrahydrothiazo[5,4-c]pyridinyl, and 4,5,6,7-tetrahydro-1H-imidazolium. Azo[4,5-c]pyridine, N-methylpiperidinyl, tetrahydroimidazolyl, pyrazolyl, butyrolactam, valproic acid, imidazolinone, hydantoin, dioxolane, phthalimide, pyrimidin-2,4(1H,3H)-diketoyl, 1,4-dioxane, morpholinyl, thiomorpholinyl, thiomorpholin-S-oxide, thiomorpholin-S,S-oxide, piperazine, pyranyl, pyridinone, 3-pyrrololinyl, thiaranyl, pyranone, tetrahydrothiophene, 2-azaspiro[3,3]heptyl, indololinyl,

[0108] Unless otherwise specified, "oxo" refers to =O; for example, a group formed by substituting carbon with an oxo group is a "carbonyl". The group formed by the substitution of sulfur with one oxo group is called "thionyl". The group formed by the substitution of sulfur with two oxo groups is called a sulfonyl group. ".

[0109] Unless otherwise specified, "halogen" (or halogenated group) means fluorine, chlorine, bromine or iodine. The term "halogenated" (or "halogen substituted") appearing before the group name indicates that the group is partially or completely halogenated, that is, substituted by F, Cl, Br or I in any combination, preferably substituted by F or Cl.

[0110] "Optional" or "optionally" means that the event or condition described below may, but is not required, occur, and the description includes both the scenario in which the event or condition occurs and the scenario in which the event or condition does not occur.

[0111] The substituent "-O-CH2-O-" indicates that the two oxygen atoms in the substituent are connected to two adjacent carbon atoms of a heterocyclic alkyl, aryl, or heteroaryl group. For example:

[0112] When the number of a linking group is 0, such as -(CH2)0-, it indicates that the linking group is a single bond.

[0113] When one of the variables is selected as a chemical bond, it means that the two groups connected are directly linked. For example, when L in XLY represents a chemical bond, it means that the structure is actually XY.

[0114] The term "membered ring" includes any ring structure. The term "membered" refers to the number of skeleton atoms that make up the ring. For example, cyclohexyl, pyridyl, pyranyl, and thioranyl are six-membered rings, while cyclopentyl, pyrroleyl, furanyl, and thiophenyl are five-membered rings.

[0115] The term "fragment" refers to a specific part or functional group of a molecule. Chemical fragments are generally considered to be chemical entities contained in or attached to a molecule.

[0116] Unless otherwise specified, use wedge-shaped solid line keys. and wedge-shaped dashed key The absolute configuration of the center of a solid is represented by a straight solid line key. and straight dashed key The relative configuration of the center of a solid is indicated by a wavy line. Indicates wedge-shaped solid line key or wedge-shaped dashed key Or use wavy lines Indicates a straight solid line key Or straight dashed key

[0117] Unless otherwise stated, use Indicates a single bond or a double bond.

[0118] Specific pharmaceutical and medical terminology

[0119] The term “acceptable,” as used herein, means that a prescription component or active ingredient does not have an excessively harmful effect on health for general therapeutic purposes.

[0120] The terms “treatment,” “treatment process,” or “therapy” as used herein include alleviating, suppressing, or improving symptoms or conditions of a disease; suppressing the development of complications; improving or preventing underlying metabolic syndromes; suppressing the development of a disease or symptom, such as controlling the progression of a disease or condition; reducing a disease or symptom; alleviating a disease or symptom; reducing complications arising from a disease or symptom; or preventing or treating signs arising from a disease or symptom. As used herein, a compound or pharmaceutical composition, when administered, may improve a disease, symptom, or condition, particularly by improving its severity, delaying its onset, slowing its progression, or reducing its duration. Whether administered regularly or intermittently, continuously or intermittently, it may be attributable to or related to the administration.

[0121] "Active ingredient" refers to the compound represented by general formula (1), and pharmaceutically acceptable inorganic or organic salts of compounds of general formula (1). The compounds of the present invention may contain one or more asymmetric centers (chiral centers or axial chirality), and thus appear as racemates, racemic mixtures, single enantiomers, diastereomers, and single diastereomers. The asymmetric centers that may exist depend on the nature of the various substituents on the molecule. Each such asymmetric center will independently produce two optical isomers, and all possible optical isomers and diastereomer mixtures, as well as pure or partially pure compounds, are included within the scope of the present invention. The present invention means including all such isomeric forms of these compounds.

[0122] The terms “compound,” “composition,” “agent,” or “medicine or medicament” may be used interchangeably here, and all refer to a compound or composition that, when applied to an individual (human or animal), can induce a desired pharmaceutical and / or physiological response through local and / or systemic action.

[0123] The term “administered, administering, or administration” here refers to the direct application of the compound or composition described herein, or the application of a prodrug, derivative, or analog of the active compound.

[0124] While the numerical ranges and parameters used to define the broader scope of this invention are approximate values, the relevant values ​​in the specific embodiments have been presented as precisely as possible. However, any value inevitably contains standard deviations due to individual test methods. Here, "approximately" generally means that the actual value is within plus or minus 10%, 5%, 1%, or 0.5% of a particular value or range. Alternatively, the term "approximately" may mean that the actual value falls within the acceptable standard error of the mean, as determined by those skilled in the art. Except for experimental examples, or unless explicitly stated otherwise, it is understood that all ranges, quantities, values, and percentages used herein (e.g., to describe material usage, duration, temperature, operating conditions, quantity ratios, and others similar) are modified with "approximately". Therefore, unless otherwise stated, the numerical parameters disclosed in this specification and the accompanying claims are approximate values ​​and are subject to change as needed. At a minimum, these numerical parameters should be understood as the indicated significant digits and values ​​obtained using general rounding.

[0125] Unless otherwise defined in this specification, scientific and technical terms used herein have the same meaning as commonly understood by those skilled in the art. Furthermore, unless conflicting with the context, singular nouns used herein include their plural forms, and vice versa.

[0126] Therapeutic uses

[0127] The compounds or pharmaceutical compositions of general formula (1) provided by this invention are generally used to inhibit the KRas G12D protein and are therefore used to treat one or more conditions associated with KRas G12D protein activity. Therefore, in some embodiments, this invention provides a method for treating KRas G12D protein-mediated conditions, the method comprising the step of administering the compounds of this invention, or pharmaceutically acceptable compositions thereof, to a patient in need.

[0128] In some embodiments, a method for treating cancer is provided, comprising administering to an individual in need an effective amount of any of the aforementioned pharmaceutical compositions comprising a compound of general structural formula (1). In some embodiments, the cancer is mediated by the KRasG12D protein. In other embodiments, the cancer is a hematologic malignancy and a solid tumor, including but not limited to leukemia, breast cancer, lung cancer, pancreatic cancer, colon cancer, bladder cancer, brain cancer, urothelial carcinoma, prostate cancer, liver cancer, ovarian cancer, head and neck cancer, gastric cancer, mesothelioma, or metastatic cancers.

[0129] route of administration

[0130] The compounds of this invention and their pharmaceutically acceptable salts can be formulated into various preparations, comprising, within a safe and effective range, the compounds of this invention or their pharmaceutically acceptable salts and pharmacologically acceptable excipients or carriers. "Safe and effective range" refers to an amount of the compound sufficient to significantly improve the condition without causing serious side effects. The safe and effective range of the compound is determined based on the age, condition, and duration of treatment of the patient.

[0131] "Pharmaceutically acceptable excipients or carriers" refers to one or more compatible solid or liquid fillers or gelling substances that are suitable for human use and must have sufficient purity and sufficiently low toxicity. "Compatibility" here means that the components in the composition can be mixed with and with the compounds of the present invention without significantly reducing the efficacy of the compounds. Examples of pharmacologically acceptable excipients or carriers include cellulose and its derivatives (such as sodium carboxymethyl cellulose, sodium ethyl cellulose, cellulose acetate, etc.), gelatin, talc, solid lubricants (such as stearic acid, magnesium stearate), calcium sulfate, vegetable oils (such as soybean oil, sesame oil, peanut oil, olive oil, etc.), polyols (such as propylene glycol, glycerin, mannitol, sorbitol, etc.), and emulsifiers (such as Tween). Wetting agents (such as sodium dodecyl sulfate), colorants, flavoring agents, stabilizers, antioxidants, preservatives, pyrogen-free water, etc.

[0132] When applying the compounds of this invention, they can be administered orally, rectally, parenterally (intravenously, intramuscularly, or subcutaneously), or topically.

[0133] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In these solid dosage forms, the active compound is mixed with at least one conventional inert excipient (or carrier), such as sodium citrate or dicalcium phosphate, or with the following components: (a) fillers or compatibilizers, such as starch, lactose, sucrose, glucose, mannitol, and silica; (b) binders, such as hydroxymethyl cellulose, alginate, gelatin, polyvinylpyrrolidone, sucrose, and gum arabic; (c) humectants, such as glycerin; (d) disintegrants, such as agar, calcium carbonate, potato starch or cassava starch, alginate, certain complex silicates, and sodium carbonate; (e) slowing agents, such as paraffin; (f) absorption accelerators, such as quaternary ammonium compounds; (g) wetting agents, such as cetyl alcohol and glyceryl monostearate; (h) adsorbents, such as kaolin; and (i) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycol, sodium dodecyl sulfate, or mixtures thereof. Buffers may also be included in capsules, tablets, and pills.

[0134] Solid dosage forms such as tablets, sugar pills, capsules, pellets, and granules can be prepared using coatings and shells, such as casings and other materials known in the art. They may contain opacifying agents, and the release of the active compound or compound from such compositions can be delayed in a portion of the digestive tract. Examples of encapsulating components that can be used are polymeric substances and waxes. If necessary, the active compound may also be formed into microcapsules with one or more of the excipients described above.

[0135] Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, or tinctures. In addition to the active compound, liquid dosage forms may contain inert diluents conventionally used in the art, such as water or other solvents, solubilizers and emulsifiers, e.g., ethanol, isopropanol, ethyl carbonate, ethyl acetate, propylene glycol, 1,3-butanediol, dimethylformamide, and oils, particularly cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil, and sesame oil, or mixtures of these substances.

[0136] In addition to these inert diluents, the composition may also contain auxiliaries such as wetting agents, emulsifiers and suspending agents, sweeteners, flavoring agents and fragrances.

[0137] In addition to the active compound, the suspension may contain suspending agents such as ethoxylated isooctadecyl alcohol, polyoxyethylene sorbitol and dehydrated sorbitol esters, microcrystalline cellulose, aluminum methoxide and agar, or mixtures of these substances.

[0138] Compositions for parenteral injection may comprise physiologically acceptable sterile aqueous or anhydrous solutions, dispersions, suspensions, or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Suitable aqueous and non-aqueous carriers, diluents, solvents, or excipients include water, ethanol, polyols, and suitable mixtures thereof.

[0139] Dosage forms of the compounds of the present invention for topical administration include ointments, powders, patches, sprays, and inhalers. The active ingredient is mixed under sterile conditions with a physiologically acceptable carrier and any preservatives, buffers, or propellants that may be necessary.

[0140] The compounds of this invention can be administered alone or in combination with other pharmaceutically acceptable compounds. When using the pharmaceutical composition, a safe and effective amount of the compound of this invention is applied to the mammal (such as a human) requiring treatment, wherein the dose administered is a pharmaceutically considered effective dose. For a person weighing 60 kg, the daily dose is typically 1–2000 mg, preferably 50–1000 mg. Of course, the specific dosage should also consider factors such as the route of administration and the patient's health condition, which are all within the scope of a skilled physician's expertise.

[0141] The features mentioned above in this invention, or the features mentioned in the embodiments, can be combined arbitrarily. All features disclosed in this specification can be used in any compositional form, and each feature disclosed in the specification can be replaced by any alternative feature that provides the same, equivalent, or similar purpose. Therefore, unless otherwise specified, the disclosed features are merely general examples of equivalent or similar features. Detailed Implementation

[0142] The following description will elaborate on the specific aspects, characteristics, and advantages of the aforementioned compounds, methods, and pharmaceutical compositions, making the content of this invention readily apparent. It should be understood that the detailed descriptions and examples described below are specific embodiments and are for reference only. After reading this description, those skilled in the art can make various alterations or modifications to this invention, and these equivalent forms also fall within the scope defined by this application.

[0143] In all embodiments, 1 H-NMR was recorded using a Varian Mercury 400 NMR spectrometer, and chemical shifts are expressed as δ (ppm). Unless otherwise specified, the silica gel used for separation was 200-300 mesh, and all eluent ratios were by volume.

[0144] The following abbreviations are used in this invention: Ac2O represents acetic anhydride; (Boc)2O represents di-tert-butyl dicarbonate; CDCl3 represents deuterated chloroform; CO represents carbon monoxide; Cs2CO3 represents cesium carbonate; CsF represents cesium fluoride; EtOAc represents ethyl acetate; Hexane represents n-hexane; HPLC represents high performance liquid chromatography; MeCN or CH3CN represents acetonitrile; DCM represents dichloromethane; DIPEA represents diisopropylethylamine; Dioxane represents 1,4-dioxane; DMF represents N,N-dimethylformamide. DMAP represents 4-(dimethylamino)pyridine; DMSO represents dimethyl sulfoxide; Dichloro(p-cymene)ruthenium(II)dimer represents dichloro(p-methylisopropylbenzene)ruthenium(II) dimer; DPPA represents diphenyl azidophosphate; EtOH represents ethanol; hr represents hours; K2CO3 represents potassium carbonate; KOAc represents potassium acetate; K3PO4 represents potassium phosphate; LiAlH4 represents lithium aluminum hydride; LiHMDS represents bis(trimethylsilyl)aminolithium; min represents minutes; MeO H represents methanol; MS represents mass spectrometry; MOMCl represents chloromethyl methyl ether; MOM represents methoxymethyl; MTBE represents tert-butyl methyl ether; NaHCO3 represents sodium bicarbonate; Na2SO4 represents sodium sulfate; n-BuLi represents n-butyllithium; NMR represents nuclear magnetic resonance; NIS represents iodosuccinimide; Pd / C represents palladium on carbon; Pd(dppf)Cl2 represents [1,1′-bis(diphenylphosphine)ferrocene]palladium(II) dichloride; Pd(PPh3)2Cl2 represents bis(triphenylphosphine)palladium dichloride; PE represents petroleum ether; POCl3 represents phosphorus oxychloride; psi represents pounds per square inch; SOCl2 represents thionyl chloride; t-BuOH represents tert-butanol; TEA represents triethylamine; TFA represents trifluoroacetic acid; Tf2O represents trifluoromethanesulfonic anhydride; THF represents tetrahydrofuran; TIPS represents triisopropylsilyl; Toluene or Tol represents toluene; XantPhos represents 4,5-bis(diphenylphosphine-9,9-dimethyloxanthracene); TLC represents thin-layer chromatography; XPhos represents 2-dicyclohexylphosphine-2′,4′,6′-triisopropylbiphenyl.

[0145] Synthesis of intermediate Int_A-1 in Preparation Example 1

[0146]

[0147] Step 1: Synthesis of compound int_A-1-2

[0148]

[0149] Int_A-1-1 hydrochloride (31 g, 178.13 mmol) was dissolved in water (500 mL). NaHCO3 (37.41 g, 445.34 mmol) was added at room temperature, and the mixture was stirred for 30 minutes. Acetic anhydride (20.00 g, 195.95 mmol, 18.35 mL) was then added to the reaction mixture, and the mixture was stirred at room temperature for another 4 hours, resulting in the precipitation of a white solid. LC-MS analysis showed that the reaction was complete. The mixture was filtered to obtain a filter cake, which was washed with water (50 mL x 2) and dried to obtain the crude product. The crude product was slurried with MTBE (300 mL) at room temperature for 30 minutes, filtered to obtain another filter cake, and dried to obtain a white solid (18 g, yield: 56.3%).

[0150] 1 H NMR: (400MHz, CHLOROFORM-d) δ = 6.40 (br s, 1H), 5.06-4.97 (m, 1H), 4.05-3.98 (m, 1H), 3.95-3.89 (m, 1H), 3.87-3.81 (m, 3H), 2.15-2.06 (m, 3H)

[0151] Step 2: Synthesis of compound int_A-1-4

[0152]

[0153] Int_A-1-2 (17.01 g, 94.74 mmol) and Int_A-1-3 (10 g, 72.87 mmol) were dissolved in acetonitrile (100 mL). A solution of DIPEA (9.42 g, 72.87 mmol, 12.69 mL) in acetonitrile (100 mL) was added dropwise at 0 °C. After stirring at room temperature for 16 hours, LC-MS analysis showed the reaction was complete. 3 mL of water was added to the reaction mixture, and stirring continued for 3 hours. The reaction mixture was concentrated under reduced pressure to obtain the crude product. The crude product was subjected to column chromatography (SiO2, Petroleum ether / Ethyl acetate = 10 / 1 to 0 / 1) to give a yellow oily substance (10 g, yield: 60.4%).

[0154] 1 H NMR: (400MHz, CHLOROFORM-d) δ = 6.80-6.33 (m, 1H), 4.74-4.57 (m, 1H), 3.76 (d, J = 2. 0Hz,3H),2.48-2.08(m,5H),2.07-1.99(m,4H),1.95-1.76(m,2H),1.63-1.54(m,1H)

[0155] Step 3: Synthesis of compound int_A-1-5

[0156]

[0157] Int_A-1-4 (10 g, 44.00 mmol) was dissolved in 10% hydrochloric acid (320.88 g, 880.06 mmol, 314.59 mL). The mixture was heated to 80 °C and reacted for 3 hours. LC-MS analysis showed that the reaction was complete. The reaction solution was concentrated under reduced pressure to obtain the crude product. The crude product could be used directly in the next reaction (8 g, yield: 95.9%).

[0158] Step 4: Synthesis of compound int_A-1-6

[0159]

[0160] Int_A-1-5 (8 g, 52.23 mmol) and Pd / C (3 g, 5.22 mmol, 10% purity) were dissolved in ethanol (200 mL). The mixture was hydrogenated at 15 psi for 16 hours, and LC-MS analysis showed that the reaction was complete. The filtrate was filtered and concentrated under reduced pressure to obtain the crude product. The crude product could be used directly in the next reaction (8 g, yield: 98.7%).

[0161] Step 5: Synthesis of compound int_A-1-7

[0162]

[0163] Int_A-1-6 (7 g, 45.10 mmol) was dissolved in methanol (200 mL), and SOCl2 (10.73 g, 90.21 mmol, 6.54 mL) was slowly added dropwise at 20 °C. The reaction mixture was stirred at room temperature for 16 hours, and LC-MS analysis showed that the reaction was complete. The reaction mixture was concentrated under reduced pressure to obtain the crude product. The crude product could be used directly in the next reaction step (8 g, yield: 105%).

[0164] Step 6: Synthesis of compound int_A-1-8

[0165]

[0166] Int_A-1-6 (8 g, 47.3 mmol) was dissolved in dichloromethane (200 mL). TEA (23.92 g, 236 mmol, 32.9 mL) and Boc2O (12.38 g, 56.73 mmol, 13.03 mL) were added at room temperature. The reaction mixture was stirred at room temperature for 16 hours, and LC-MS analysis showed that the reaction was complete. The reaction mixture was concentrated under reduced pressure to obtain the crude product. The crude product was subjected to column chromatography (SiO2, Petroleum ether / Ethyl acetate = 4 / 1) to give a colorless oil (10 g, yield: 78.5%).

[0167] 1 H NMR: (400MHz, CHLOROFORM-d)δ=4.46-4.12(m,2H),3.77-3.68(m,3H),2.75-2.63( m,1H),2.49-2.33(m,1H),2.04-1.86(m,2H),1.84-1.73(m,2H),1.51-1.34(m,11H)

[0168] Step 7: Synthesis of compound int_A-1-10

[0169]

[0170] Int_A-1-8 (9.1 g, 33.79 mmol) was dissolved in THF (160 mL), and LiHMDS (1 M, 54.06 mL) was slowly added dropwise at -60 °C. After stirring the reaction solution at -60 °C for 1 hour, Int_A-1-9 (7.98 g, 50.68 mmol, 4.99 mL) was added to the reaction solution, and the reaction solution was stirred at -60 °C for another hour. Then, the reaction was brought to room temperature for 2 hours, and LC-MS analysis showed that the reaction was complete. 10 mL of saturated ammonium chloride aqueous solution and 20 mL of water were added to the reaction solution. The aqueous phase was extracted with ethyl acetate (30 mL x 3), and the organic phase was washed with saturated brine and dried over anhydrous sodium sulfate. The organic phase was concentrated under reduced pressure to obtain the crude product, which was then subjected to column chromatography (SiO2, Petroleum ether / Ethyl acetate = 100 / 1 to 15 / 1) to give a yellow gel (6 g, yield: 51.3%).

[0171] 1H NMR: (400MHz, CHLOROFORM-d) δ = 4.41-4.09 (m, 1H), 3.76-3.69 (m, 3H), 3.66-3.49 (m, 2H), 2. 85-2.65(m,1H),2.40-2.24(m,1H),2.21-2.06(m,1H),2.05-1.63(m,8H),1.55-1.37(m,11H)

[0172] Step 8: Synthesis of compound int_A-1-11

[0173]

[0174] Int_A-1-10 (6 g, 17.35 mmol) was dissolved in dichloromethane (10 mL), and dioxane hydrochloride solution (4 M, 43.37 mL) was slowly added dropwise while maintaining the temperature below 10 °C. The reaction mixture was stirred at room temperature for 3 hours, and LC-MS analysis showed that the reaction was complete. The reaction mixture was concentrated under reduced pressure to obtain the crude product. The crude product could be used directly in the next reaction step (5 g, yield: 117%).

[0175] Step 9: Synthesis of compound int_A-1-12

[0176]

[0177] Int_A-1-11 hydrochloride (5 g, 17.72 mmol) was dissolved in methanol (150 mL), and K2CO3 (7.35 g, 53.15 mmol) was added at room temperature. The reaction mixture was stirred at room temperature for 16 hours, and LC-MS analysis showed that the reaction was complete. The reaction mixture was filtered to obtain a filtrate, which was then concentrated under reduced pressure to obtain a crude product. The crude product was subjected to column chromatography (SiO2, DCM / MeOH = 10 / 1) to give a yellow oily substance (2.5 g, yield: 67.4%).

[0178] 1 H NMR: (400MHz, CHLOROFORM-d)δ=3.76-3.69(m,3H),3.30-3.24(m,1H),3.14(td,J=6.9,11.1Hz,1H ),2.88-2.80(m,1H),2.70-2.58(m,1H),2.24-2.16(m,2H),2.14-2.05(m,1H),1.94-1.36(m,10H)

[0179] Step 10: Synthesis of compound int_A-1

[0180]

[0181] Int_A-1-12 (2.3 g, 10.99 mmol) was dissolved in THF (50 mL), and LiAlH4 (834 mg, 21.98 mmol) was added at 0 °C. The reaction mixture was stirred at room temperature for 2 hours, and LC-MS analysis showed that the reaction was complete. 10·H2O·Na2SO4 (20 g) was added to the reaction mixture at 0 °C, and the mixture was brought to room temperature and stirred for another 30 minutes. The reaction mixture was filtered to obtain a filtrate, which was then concentrated under reduced pressure to obtain a crude product. The crude product was suspended in dichloromethane (10 mL), filtered again, and the filtrate was concentrated under reduced pressure to obtain a yellow oily substance (1.5 g, yield: 75.3%).

[0182] 1 H NMR: (400MHz, CHLOROFORM-d) δ = 3.31-3.20 (m, 2H), 3.18-3.11 (m, 1H), 2.92-2.77 (m, 2H) ,2.69-2.57(m,1H),2.04-1.91(m,2H),1.80(dd,J=7.2,12.9Hz,1H),1.76-1.44(m,12H)

[0183] Preparation Example 2: Synthesis of intermediate Int_A-2

[0184]

[0185] Step 1: Synthesis of compound int_A-2-2

[0186]

[0187] Int_A-2-1 hydrochloride (75 g, 430.97 mmol) was dissolved in water (1000 mL). NaHCO3 (90.51 g, 1.08 mol) was added at room temperature, and the mixture was stirred for 30 minutes. Acetic anhydride (48.40 g, 474.07 mmol, 44.40 mL) was then added to the reaction mixture, and the mixture was stirred at room temperature for another 4 hours, resulting in the precipitation of a white solid. LC-MS analysis showed that the reaction was complete. The mixture was filtered to obtain a filter cake, which was washed with water (50 mL x 2) and dried to obtain the crude product. The crude product was slurried with MTBE (500 mL) at room temperature for 30 minutes, filtered to obtain another filter cake, and dried to obtain a white solid (40 g, yield: 51.7%).

[0188] 1H NMR: (400MHz, CHLOROFORM-d) δ = 6.41 (br s, 1H), 5.08-4.99 (m, 1H), 4.03-3.97 (m, 1H), 3.96-3.89 (m, 1H), 3.84 (s, 3H), 2.10 (s, 3H)

[0189] Step 2: Synthesis of compound int_A-2-4

[0190]

[0191] Int_A-2-2 (25 g, 182.19 mmol, 26.57 mL) and Int_A-2-3 (39.27 g, 218.62 mmol) were dissolved in acetonitrile (300 mL). A solution of DIPEA (23.55 g, 182.19 mmol, 31.73 mL) in acetonitrile (300 mL) was added dropwise at 0 °C. After stirring at room temperature for 16 hours, LC-MS analysis showed the reaction was complete. 3 mL of water was added to the reaction mixture, and stirring continued for 3 hours. The reaction mixture was concentrated under reduced pressure to obtain the crude product. The crude product was subjected to column chromatography (SiO2, Petroleum ether / Ethylacetate = 10 / 1 to 0 / 1) to give a yellow oily substance (24 g, yield: 57.9%).

[0192] 1 H NMR: (400MHz, CHLOROFORM-d) δ = 6.82-6.37 (m, 1H), 4.74-4.55 (m, 1H), 3.76 (d, J = 2. 0Hz,3H),2.49-2.32(m,2H),2.31-2.00(m,9H),1.94-1.78(m,2H),1.64-1.54(m,1H)

[0193] Step 3: Synthesis of compound int_A-2-5

[0194]

[0195] Int_A-2-4 (25 g, 110.01 mmol) was dissolved in 10% hydrochloric acid (401.10 g, 1.10 mol, 393.23 mL). The mixture was heated to 80 °C and reacted for 3 hours. LC-MS analysis showed that the reaction was complete. The reaction solution was concentrated under reduced pressure to obtain the crude product. The crude product (18 g, crude product) could be used directly in the next reaction.

[0196] Step 4: Synthesis of compound int_A-2-6

[0197]

[0198] Int_A-2-5 (15 g, 97.93 mmol) and Pd / C (1.5 g, 10% purity) were dissolved in ethanol (40 mL). The mixture was hydrogenated at 15 psi for 16 hours, and LC-MS analysis showed that the reaction was complete. The filtrate was obtained by filtration and then concentrated under reduced pressure to obtain the crude product. The crude product could be used directly in the next reaction (15 g, crude product).

[0199] Step 5: Synthesis of compound int_A-2-7

[0200]

[0201] Int_A-2-6 (15 g, 96.65 mmol) was dissolved in methanol (200 mL), and SOCl2 (23.00 g, 193.31 mmol, 14.02 mL) was slowly added dropwise at 20 °C. The reaction mixture was stirred at room temperature for 16 hours, and LC-MS analysis showed that the reaction was complete. The reaction mixture was concentrated under reduced pressure to obtain the crude product. The crude product (16 g, crude product) could be used directly in the next reaction step.

[0202] Step 6: Synthesis of compound int_A-2-8

[0203]

[0204] Int_A-2-6 (16 g, 94.55 mmol) was dissolved in dichloromethane (200 mL). TEA (61.10 g, 472.76 mmol, 82.35 mL) and Boc2O (30.95 g, 141.83 mmol, 32.58 mL) were added at room temperature. The reaction mixture was stirred at room temperature for 16 hours, and LC-MS analysis showed that the reaction was complete. The reaction mixture was concentrated under reduced pressure to obtain the crude product. The crude product was subjected to column chromatography (SiO2, Petroleum ether / Ethyl acetate = 4 / 1) to give a colorless oil (16 g, yield: 62.83%).

[0205] 1 H NMR: (400MHz, CHLOROFORM-d) δ = 4.47-4.13 (m, 2H), 3.82-3.71 (m, 3H), 2.76-2.63 (m, 1H), 2.49-2.34(m,1H),2.04-1.87(m,2H),1.87-1.66(m,3H),1.61(s,4H),1.57-1.34(m,10H)

[0206] Step 7: Synthesis of compound int_A-2-10

[0207]

[0208] Int_A-2-8 (16 g, 59.41 mmol) was dissolved in THF (300 mL), and LiHMDS (1 M, 89.11 mL) was slowly added dropwise at -60 °C. After stirring the reaction solution at -60 °C for 1 hour, Int_A-2-9 (14.03 g, 89.11 mmol, 8.77 mL) was added to the reaction solution, and the reaction solution was stirred at -60 °C for another hour, then the reaction was allowed to proceed to room temperature for 2 hours. LC-MS analysis showed that the reaction was complete. 100 mL of saturated ammonium chloride aqueous solution and 100 mL of water were added to the reaction solution. The aqueous phase was extracted with ethyl acetate (150 mL x 3), and the organic phase was washed with saturated brine and dried over anhydrous sodium sulfate. The organic phase was concentrated under reduced pressure to obtain the crude product, which was then subjected to column chromatography (SiO2, Petroleum ether / Ethyl acetate = 100 / 1 to 15 / 1) to obtain a yellow gel (17 g, yield: 82.7%).

[0209] 1 H NMR: (400MHz, CHLOROFORM-d) δ = 4.34-4.10 (m, 1H), 3.78-3.70 (m, 3H), 3.66-3.49 (m, 2H), 2.8 2-2.70(m,1H),2.37-2.24(m,1H),2.21-2.07(m,1H),2.04-1.56(m,10H),1.53-1.38(m,11H)

[0210] Step 8: Synthesis of compound int_A-2-11

[0211]

[0212] Int_A-2-10 (17 g, 49.15 mmol) was dissolved in dichloromethane (50 mL), and dioxane hydrochloride solution (4 M, 122.88 mL) was slowly added dropwise while maintaining the temperature below 10 °C. The reaction mixture was stirred at room temperature for 3 hours, and LC-MS analysis showed that the reaction was complete. The reaction mixture was concentrated under reduced pressure to obtain the crude product. The crude product could be used directly in the next reaction step (12 g, yield: 99.35%).

[0213] Step 9: Synthesis of compound int_A-2-12

[0214]

[0215] Int_A-2-11 (12 g, 48.83 mmol) was dissolved in methanol (200 mL), and K2CO3 (20.25 g, 146.49 mmol) was added at room temperature. The reaction mixture was stirred at room temperature for 16 hours, and LC-MS analysis showed that the reaction was complete. The reaction mixture was filtered to obtain a filtrate, which was then concentrated under reduced pressure to obtain a crude product. The crude product was subjected to column chromatography (SiO2, DCM / MeOH = 10 / 1) to give a yellow oily substance (7 g, yield: 68.50%).

[0216] 1 H NMR: (400MHz, CHLOROFORM-d)δ=3.76-3.69(m,3H),3.30-3.24(m,1H),3.14(td,J=6.9,11.1Hz,1H ),2.88-2.80(m,1H),2.70-2.58(m,1H),2.24-2.16(m,2H),2.14-2.05(m,1H),1.94-1.36(m,10H)

[0217] Step 10: Synthesis of compound int_A-2

[0218]

[0219] Int_A-2-12 (7 g, 33.45 mmol) was dissolved in THF (150 mL), and LiAlH4 (2.54 g, 66.89 mmol) was added at 0 °C. The reaction mixture was stirred at room temperature for 2 hours, and LC-MS analysis showed that the reaction was complete. 10·H2O·Na2SO4 (50 g) was added to the reaction mixture at 0 °C, and the mixture was brought to room temperature and stirred for another 30 minutes. The reaction mixture was filtered to obtain a filtrate, which was then concentrated under reduced pressure to obtain a crude product. The crude product was suspended in dichloromethane (10 mL), filtered again, and the filtrate was concentrated under reduced pressure to obtain a yellow oily substance (5 g, yield: 82.5%).

[0220] Synthesis of intermediate Int_B-1 in Preparation Example 3

[0221]

[0222] Step 1: Synthesis of compound int_B-1-3

[0223]

[0224] Int_B-1-1 (25 g, 156 mmol), Int_B-1-2 (49 g, 188 mmol), Dichloro(p-cymene)ruthenium(II)dimer (9.5 g, 15.6 mmol), and potassium acetate (30.6 g, 312 mmol) were dissolved in dioxane (300 mL). The reaction solution was reacted at 110 °C for 12 hours, and LC-MS analysis showed that the reaction was complete. 500 mL of water was added to the reaction solution, and the aqueous phase was extracted with ethyl acetate (500 mL x 3). The organic phase was washed with saturated brine and dried over anhydrous sodium sulfate. The organic phase was concentrated under reduced pressure to obtain the crude product, which was then subjected to column chromatography (SiO2, Petroleum ether / Ethyl acetate = 3 / 1) to obtain the product (46 g, yield: 86.7%).

[0225] ESI-MS m / z: 341 [M+H] + .

[0226] Step 2: Synthesis of compound int_B-1-4

[0227]

[0228] Int_B-1-3 (90 g, 264.5 mmol) and DIPEA (103 g, 0.8 mol, 138 mL) were dissolved in dichloromethane (800 mL). MOMCl (31.9 g, 396.5 mmol, 30.1 mL) was added at 0 °C. The reaction mixture was allowed to react at 0 °C for half an hour, and LC-MS analysis showed complete reaction. 600 mL of water was added to the reaction mixture, and the aqueous phase was extracted with dichloromethane (300 mL x 3). The organic phase was washed with saturated brine and dried over anhydrous sodium sulfate. The organic phase was concentrated under reduced pressure to obtain the crude product, which was then subjected to column chromatography (SiO2, Petroleum ether / Ethyl acetate = 3 / 1) to obtain the final product (51 g, yield: 50.5%).

[0229] 1 H NMR (400MHz, CHLOROFORM-d) δ = 9.26 (s, 1H), 7.70 (dd, J = 0.8, 8.0Hz, 1H), 7.50 (dd, J = 1.2, 7.2Hz, 1H), 7.32 (dd, J=7.2,8.4Hz,1H),6.99(d,J=2.4Hz,1H),6.78(d,J=2.4Hz,1H),5.28(s,2H),3.52(s,3H),1.20-1.16(m,21H).

[0230] Step 3: Synthesis of compound int_B-1-5

[0231]

[0232] Int_B-1-4 (100 g, 260 mmol) and DIPEA (101 g, 0.78 mol, 136 mL) were dissolved in dichloromethane (1200 mL). Tf₂O (110 g, 390 mmol, 64.5 mL) was added at -40 °C. The reaction mixture was allowed to react at -40 °C for half an hour, and LC-MS analysis showed complete reaction. The reaction was quenched with 800 mL of water. The aqueous phase was extracted with dichloromethane (500 mL x 3). The organic phase was washed with saturated brine and dried over anhydrous sodium sulfate. The organic phase was concentrated under reduced pressure to obtain the crude product. The crude product was subjected to column chromatography (SiO₂, Petroleum ether / Ethyl acetate = 5 / 1) to obtain the final product (115 g, yield: 85.8%).

[0233] Step 4: Synthesis of compound int_B-1

[0234]

[0235] Int_B-1-5 (115 g, 222.5 mmol), Int_B-1-6 (113 g, 445 mmol), Pd(dppf)Cl2 (16.3 g, 23 mmol), and potassium acetate (76 g, 0.78 mol) were dissolved in toluene (800 mL). The reaction solution was reacted at 110 °C for 3 hours under nitrogen protection, and LC-MS analysis showed that the reaction was complete. 500 mL of water was added to the reaction solution, and the aqueous phase was extracted with ethyl acetate (500 mL x 3). The organic phase was washed with saturated brine and dried over anhydrous sodium sulfate. The organic phase was concentrated under reduced pressure to obtain the crude product, which was then subjected to column chromatography (SiO2, Petroleum ether / Ethyl acetate = 20 / 1) to obtain the product (56 g, yield: 50.9%).

[0236] 1 H NMR(400MHz,CHLOROFORM-d)δ=7.71-7.66(m,2H),7.47(d,J=2.4Hz,1H),7.3 9-7.32(m,2H),5.28(s,2H),3.52(s,3H),1.43(s,12H),1.19-1.15(m,21H).

[0237] Example 1: Synthesis of Compound 2

[0238]

[0239] Step 1: Synthesis of compound int_2-2

[0240]

[0241] Int2-1 (60 g, 343 mmol), TEA (103.5 g, 1.03 mol, 142.6 mL), tert-butanol (336.7 g, 4.53 mol, 433 mL), and DPPA (26 g, 0.26 mol) were dissolved in toluene (400 mL). The reaction mixture was reacted at 110 °C for 6 hours under nitrogen protection, and LC-MS analysis showed that the reaction was complete. 600 mL of water was added to the reaction mixture, and the aqueous phase was extracted with ethyl acetate (500 mL x 3). The organic phase was washed with saturated brine and dried over anhydrous sodium sulfate. The organic phase was concentrated under reduced pressure to obtain the crude product, which was then subjected to column chromatography (SiO2, Petroleum ether / Ethyl acetate = 100 / 1 to 5 / 1) to give the product (59 g, yield: 69.7%).

[0242] 1 H NMR (400MHz, methanol-d4) δ = 8.11 (t, J = 5.6Hz, 1H), 7.99 (d, J = 5.6Hz, 1H), 1.52 (s, 9H).

[0243] Step 2: Synthesis of compound int_2-3

[0244]

[0245] Int₂⁻ (0.95 g, 3.85 mmol) was dissolved in dichloromethane (6 mL), and TFA (3 mL) was slowly added dropwise while maintaining the temperature below 10 °C. The reaction mixture was allowed to react at room temperature for 6 hours, and LC-MS analysis showed that the reaction was complete. The reaction mixture was then concentrated under reduced pressure to obtain the crude product. The crude product was directly used in the next reaction step (564 mg, yield: 100%).

[0246] 1 H NMR (400MHz, CHLOROFORM-d): δ = 7.82 (d, J = 5.4Hz, 1H), 6.60 (t, J = 5.8Hz, 1H), 4.38 (br s, 2H).

[0247] Step 3: Synthesis of compound int_2-4

[0248]

[0249] Int2-3 (10.7 g, 73 mmol) and NIS (19.7 g, 87.6 mmol) were dissolved in acetonitrile (50 mL), and p-toluenesulfonic acid (0.7 g, 3.65 mmol) was added at room temperature. The reaction mixture was stirred at 70 °C for 16 hours, and LC-MS analysis showed that the reaction was complete. 50 mL of water was added to the reaction mixture, and the aqueous phase was extracted with ethyl acetate (50 mL x 3). The organic phase was washed with saturated brine and dried over anhydrous sodium sulfate. The organic phase was concentrated under reduced pressure to obtain the crude product, which could be used directly in the next reaction (18 g, yield: 90.9%).

[0250] Step 4: Synthesis of compound int_2-5

[0251]

[0252] Int₂⁻⁴ (7.8 g, 28.8 mmol), Pd(PPh₃)₂Cl₂ (2 g, 2.88 mmol), and TEA (10.5 g, 0.1 mol, 14.5 mL) were dissolved in ethanol (200 mL). The reaction mixture was reacted at 80 °C for 16 hours under a CO atmosphere (15.0 psi), and LC-MS analysis showed that the reaction was complete. 100 mL of water was added to the reaction mixture, and the aqueous phase was extracted with ethyl acetate (100 mL x 3). The organic phase was washed with saturated brine and dried over anhydrous sodium sulfate. The organic phase was concentrated under reduced pressure to obtain the crude product, which was then subjected to column chromatography to obtain the final product (5.3 g, yield: 84.1%).

[0253] 1 H NMR (400MHz, dmso-d6) δ = 8.36 (s, 1H), 7.49-7.42 (m, 2H), 4.31 (q, J = 7.2Hz, 2H), 1.31 (t, J = 7.2Hz, 3H).

[0254] Step 5: Synthesis of compound int_2-7

[0255]

[0256] Int₂-5 (10 g, 36.5 mmol) was dissolved in THF (30 mL), and Int₂-6 (10 g, 55 mmol, 6.5 mL) was slowly added dropwise while maintaining the temperature below 10 °C. The reaction mixture was allowed to react at room temperature for 1 hour, and LC-MS analysis showed that the reaction was complete. The reaction mixture was concentrated under reduced pressure to obtain the crude product. The crude product could be used directly in the next reaction step (13.7 g, yield: 92.5%).

[0257] Step 6: Synthesis of compound int_2-8

[0258]

[0259] Int_2-7 (10 g, 21 mmol) was dissolved in methanol (100 mL). A methanol solution of ammonia (10 mL, 20% purity) was slowly added dropwise to the solution. The reaction mixture was allowed to react at room temperature for 1 hour, and LC-MS analysis showed that the reaction was complete. The reaction mixture was concentrated under reduced pressure to obtain the crude product. The crude product was then pulped in MTBE to obtain the final product (3.9 g, yield: 86.7%).

[0260] ESI-MS m / z: 216 [M+H] + .

[0261] Step 7: Synthesis of compound int_2-9

[0262]

[0263] Int_2-8 (2 g, 9.3 mmol) was dissolved in toluene (10 mL). Phosphorus oxychloride (4.3 g, 27.8 mmol, 2.6 mL) and DIPEA (3.6 g, 27.8 mmol, 4.85 mL) were slowly added dropwise to the solution at 0 °C. The reaction mixture was heated to 110 °C and reacted for 5 hours. LC-MS analysis showed that the reaction was complete. The reaction solution was concentrated under reduced pressure to obtain the crude product. The crude product was directly used in the next reaction step (2.1 g, yield: 89.7%).

[0264] Step 8: Synthesis of compound int_2-11

[0265]

[0266] Int2-9 (1.0 g, 3.961 mmol) was dissolved in DCM (25 mL), and DIPEA (2.6 g, 19.81 mmol) was added. Under nitrogen protection, a DCM solution of Int2-10 (841 mg, 3.961 mmol) was added dropwise at -40 °C (10 mL). After the addition was complete, the reaction solution was reacted at -40 °C for 0.5 hours. LC-MS showed that the reaction was complete. 50 mL of water was added to the reaction solution, and the aqueous phase was extracted with ethyl acetate (50 mL x 3). The organic phase was washed with saturated brine and dried over anhydrous sodium sulfate. The organic phase was concentrated under reduced pressure to obtain the crude product, which could be directly used in the next step of the reaction (1.65 g, 97.1%).

[0267] ESI-MS m / z: 428 [M+H] +

[0268] Step 9: Synthesis of compound int_2-12

[0269]

[0270] Int_2-11 (500 mg, 1.167 mmol) was dissolved in DMF (7 mL), and Int_A-1 (212 mg, 1.169 mmol) and cesium carbonate (760 mg, 2.338 mmol) were added. The mixture was reacted at 80 °C for 16 hours. LC-MS analysis showed that the reaction was complete. The reaction solution was concentrated under reduced pressure to obtain a crude product, which was then subjected to reversed-phase HPLC to prepare a yellow solid product (120 mg, yield: 17.1%).

[0271] ESI-MS m / z: 573 [M+H] +

[0272] Step 10: Synthesis of compound int_2-13

[0273]

[0274] Int_2-12 (120 mg, 0.209 mmol) was dissolved in a mixed solution of dioxane / water (5 mL / 1 mL), and Int_B-1 (104 mg, 0.209 mmol), potassium carbonate (43 mg, 0.314 mmol), and Ruphos-Pd-G3 (52 mg, 0.062 mmol) were added. The reaction solution was heated to 100 °C and reacted for 16 hours under protective conditions. LC-MS analysis showed that the reaction was complete. The reaction solution was concentrated under reduced pressure to obtain a crude product, which was then subjected to reversed-phase HPLC to prepare a yellow solid product (30 mg, yield: 15.8%).

[0275] ESI-MS m / z: 453 [M / 2+H] +

[0276] Step 11: Synthesis of compound int_2-14

[0277]

[0278] Int_2-13 (30 mg, 0.033 mmol) was dissolved in DMF (2 mL), and cesium fluoride (50 mg, 0.33 mmol) was added. The reaction solution was reacted at room temperature under nitrogen protection for 2 hours, and LC-MS analysis showed that the reaction was complete. 10 mL of water was added to the reaction solution, and the aqueous phase was extracted with ethyl acetate (10 mL x 3). The organic phase was washed with saturated brine and dried over anhydrous sodium sulfate. The organic phase was concentrated under reduced pressure to obtain the crude product. The crude product was then subjected to reversed-phase HPLC to prepare a yellow solid product (20 mg, yield: 79.1%).

[0279] ESI-MS m / z: 375 [M / 2+H] +

[0280] Step 12: Synthesis of Compound 2

[0281]

[0282] Int_2-14 (20 mg, 0.026 mmol) was dissolved in methanol (1 mL), cooled to -5°C in an ice bath, and 4 M dioxane hydrochloride solution (2 mL) was slowly added dropwise to the reaction solution. After the addition was complete, the reaction solution was kept at -5°C for 2 hours, and LC-MS analysis showed that the reaction was complete. The pH of the reaction solution was adjusted to 7-8 with saturated sodium bicarbonate solution, the aqueous phase was extracted with ethyl acetate (10 mL x 3), the organic phase was washed with saturated brine and dried over anhydrous sodium sulfate, and the organic phase was concentrated under reduced pressure to obtain the crude product. The crude product was then subjected to reversed-phase HPLC to prepare a yellow solid product (5 mg, 31.6%).

[0283] 1 H NMR (400MHz, Methanol-d4)δ=9.04(d,J=3.6Hz,1H),8.53(s,1H),7.82(d,J=8.2Hz,1H),7.51(dd,J=7.2,1.3H z,1H),7.44-7.37(m,1H),7.33(d,J=2.6Hz,1H),7.16(dd,J=2.6,1.4Hz,1H),4.57(dd,J=17.7,12.2Hz,6H),3. 79-3.65(m,3H),3.48(dd,J=3.3,1.6Hz,2H),3.14(dt,J=6.8,3.4Hz,2H),3.04-2.90(m,2H),2.38-2.27(m,1H ),2.17(dq,J=11.7,6.1,5.1Hz,2H),2.00(dd,J=13.5,6.7Hz,2H),1.93-1.72(m,5H).1.70-1.50(m,2H)ESI-MS m / z:605[M+H] +

[0284] Example 2 Synthesis of Compound 3

[0285]

[0286]

[0287] Step 1: Synthesis of compound int_3-1

[0288]

[0289] Int_2-11 (500 mg, 1.167 mmol) was dissolved in DMF (7 mL), and Int_A-2 (212 mg, 1.169 mmol) and cesium carbonate (760 mg, 2.338 mmol) were added. The mixture was reacted at 80 °C for 16 hours. LC-MS analysis showed that the reaction was complete. The reaction solution was concentrated under reduced pressure to obtain a crude product, which was then subjected to reversed-phase HPLC to prepare a yellow solid product (105 mg, yield: 15%).

[0290] ESI-MS m / z: 573 [M+H] +

[0291] Step 2: Synthesis of compound int_3-2

[0292]

[0293] Int_3-1 (105 mg, 0.183 mmol) was dissolved in a mixed solution of dioxane / water (5 mL / 1 mL), and Int_B-1 (91 mg, 0.183 mmol), potassium carbonate (38 mg, 0.275 mmol), and Ruphos-Pd-G3 (52 mg, 0.062 mmol) were added. The reaction solution was heated to 100 °C and reacted for 16 hours under protective conditions. LC-MS analysis showed that the reaction was complete. The reaction solution was concentrated under reduced pressure to obtain a crude product, which was then subjected to reversed-phase HPLC to prepare a yellow solid product (45 mg, yield: 27.1%).

[0294] ESI-MS m / z: 453 [M / 2+H] +

[0295] Step 3: Synthesis of compound int_3-3

[0296]

[0297] Int_3-2 (45 mg, 0.0497 mmol) was dissolved in DMF (2 mL), and cesium fluoride (75 mg, 0.497 mmol) was added. The reaction solution was reacted at room temperature under nitrogen protection for 2 hours, and LC-MS analysis showed that the reaction was complete. 10 mL of water was added to the reaction solution, and the aqueous phase was extracted with ethyl acetate (10 mL x 3). The organic phase was washed with saturated brine and dried over anhydrous sodium sulfate. The organic phase was concentrated under reduced pressure to obtain the crude product. The crude product was then subjected to reversed-phase HPLC to prepare a yellow solid product (28 mg, yield: 75.3%).

[0298] ESI-MS m / z: 375 [M / 2+H] +

[0299] Step 4: Synthesis of Compound 3

[0300]

[0301] Int_3-3 (28 mg, 0.0366 mmol) was dissolved in methanol (1.5 mL), cooled to -5°C in an ice bath, and 4 M dioxane hydrochloride solution (3 mL) was slowly added dropwise to the reaction solution. After the addition was complete, the reaction solution was kept at -5°C for 2 hours, and LC-MS analysis showed that the reaction was complete. The pH of the reaction solution was adjusted to 7-8 with saturated sodium bicarbonate solution, the aqueous phase was extracted with ethyl acetate (10 mL x 3), the organic phase was washed with saturated brine and dried over anhydrous sodium sulfate, and the organic phase was concentrated under reduced pressure to obtain the crude product. The crude product was then subjected to reversed-phase HPLC to prepare a yellow solid product (7 mg, 31.8%).

[0302] 1 H NMR (400MHz, Methanol-d4) δ = 9.08 (d, J = 4.3Hz, 1H), 8.47 (s, 1H), 7.83 (dd, J = 8.5, 1.3Hz ,1H),7.51(dd,J=7.1,1.3Hz,1H),7.43–7.32(m,2H),7.16(t,J=2.2Hz,1H),4.75–4.58( m,4H),4.03–3.89(m,3H),3.83(d,J=13.3Hz,2H),3.78–3.64(m,2H),3.54–3.42(m,1H), 3.18–3.07(m,1H),2.39(dd,J=13.9,8.7Hz,1H),2.34–1.79(m,11H),1.77–1.62(m,2H).

[0303] ESI-MS m / z: 605 [M+H] +

[0304] Synthesis of Compound 1 and Compounds 4-348 in Examples 3-348

[0305] Using the above synthetic method and different raw materials, target compound 1 and compound 4-348 in Table 1 can be obtained.

[0306] Table 1

[0307]

[0308]

[0309]

[0310]

[0311]

[0312]

[0313]

[0314]

[0315]

[0316]

[0317]

[0318]

[0319]

[0320]

[0321]

[0322]

[0323]

[0324]

[0325]

[0326]

[0327]

[0328]

[0329]

[0330] Example 349: Determination of the antiproliferative activity of the compound against Aspc-1 cells.

[0331] The human pancreatic cancer cell line Aspc-1 carrying the KRAS-G12D mutant was suspended in RPMI 1640 medium containing fetal bovine serum and seeded in 96-well ultra-low adsorption plates (Corning 7007) at a density of 2500 cells per well. The cells were cultured at 37°C for one day in an incubator containing 5% CO2. On the second day, a serially diluted compound was added, with a final concentration of 0.3% DMSO. The cells were then cultured for another 3 days at 37°C in an incubator containing 5% CO2. After mixing with Cell Titer-Glo for 10 minutes, the chemiluminescence was detected using a microplate reader, and the ATP content in the cells was measured to evaluate cell growth and calculate the IC50 (inhibition of cell growth) of the compound. 50 The results are shown in Table 2 below.

[0332] Table 2. Antiproliferative activity of the compounds of the present invention against Aspc-1 cells (IC50) 50 ,nM)

[0333] Compound <![CDATA[IC 50 ]]> Compound <![CDATA[IC 50 ]]> Compound <![CDATA[IC 50 ]]> Compound <![CDATA[IC 50 ]]> 1 ++ 2 ++ 3 +++ 4 N.D 5 N.D 6 ++ 7 ++ 8 +++ 9 N.D 10 N.D 11 ++ 12 ++ 13 ++ 14 N.D 15 N.D 16 N.D 17 ++ 18 +++ 19 N.D 20 N.D 21 N.D 22 ++ 23 ++ 24 N.D 25 N.D 26 N.D 27 ++ 28 ++ 29 N.D 30 N.D 31 N.D 32 ++ 33 ++ 34 N.D 35 N.D 36 N.D 37 ++ 38 ++ 43 +++ 44 +++ 45 ++ 46 ++ 47 N.D 48 ++ 49 ++ 50 ++ 51 ++ 52 N.D 53 +++ 54 +++ 55 +++ 56 ++ 57 N.D 58 +++ 59 +++ 60 ++ 61 ++ 62 N.D 63 ++ 64 ++ 75 ++ 76 ++ 77 ++ 78 ++ 79 N.D 80 +++ 81 +++ 82 ++

[0334] 83 ++ 84 N.D 85 +++ 86 +++ 87 ++ 88 ++ 89 N.D 90 ++ 91 ++ 92 ++ 93 ++ 94 N.D 95 ++ 96 ++ 97 ++ 98 ++ 99 N.D 100 ++ 101 ++ 102 ++ 103 ++ 104 N.D 105 N.D 106 +++ 107 +++ 108 +++ 109 +++ 110 N.D 129 N.D 130 ++ 131 ++ 132 N.D

[0335] +++ indicates IC 50 Less than or equal to 500 nM

[0336] ++ indicates IC 50 500nM to 1000nM

[0337] + indicates IC 50 Greater than 1000 nM

[0338] ND indicates that the activity was not measured.

[0339] As can be seen from the data in Table 2, the compounds of the present invention all have strong anti-proliferative activity against Aspc-1 cells.

[0340] While specific embodiments of the present invention have been described above, those skilled in the art should understand that these are merely illustrative examples, and various changes or modifications can be made to these embodiments without departing from the principles and essence of the present invention. Therefore, the scope of protection of the present invention is defined by the appended claims.

Claims

1. A compound of formula (1) or a pharmaceutically acceptable salt thereof: In general formula (1): Structural unit for: ; R 1 -H, -OH, halogen, (C1-C3)alkyl, nitrile-substituted (C1-C3)alkyl, hydroxyl-substituted (C1-C3)alkyl, HC(=O)-, -CO2R 5 or -CO2N(R) 5 )2; Y is O or NR 5 ; Structural unit for: , , , , , or ; Each R 5 It is independently -H or (C1-C3) alkyl.

2. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein in the general formula (1), R 1 -H, -OH, -F , , , , , HC(=O)-, -CO2CH3 or -CO2N(CH3)2.

3. The compound of claim 1 or 2 or a pharmaceutically acceptable salt thereof, wherein in the general formula (1), Y is O, NH or NCH3.

4. The compound of claim 1 or a pharmaceutically acceptable salt thereof, wherein the compound has one of the following structures: 。 5. A pharmaceutical composition, characterized in that, It contains a pharmaceutically acceptable excipient or carrier, and a compound or a pharmaceutically acceptable salt thereof as any one of claims 1-4 as an active ingredient.

6. The use of a compound as described in any one of claims 1-4, or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition as described in claim 5, in the preparation of a medicament for treating, modulating, or preventing KRas G12D-related diseases.

7. The application as described in claim 6, wherein the disease is cancer, and the cancer is a hematologic malignancy or a solid tumor.

Citation Information

Patent Citations

  • Quinazoline amine derivatives as KRAS inhibitors

    CN117255684A

  • KRAS g12d inhibitors

    WO2021041671A1